ID: ALA383923

Max Phase: Preclinical

Molecular Formula: C9H13N2O10P

Molecular Weight: 340.18

Molecule Type: Small molecule

Associated Items:

Representations

Synonyms (1): 6-hydroxy-UMP
Synonyms from Alternative Forms(1):

    Canonical SMILES:  O=c1cc(O)n([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1

    Standard InChI:  InChI=1S/C9H13N2O10P/c12-4-1-5(13)11(9(16)10-4)8-7(15)6(14)3(21-8)2-20-22(17,18)19/h1,3,6-8,13-15H,2H2,(H,10,12,16)(H2,17,18,19)/t3-,6-,7-,8-/m1/s1

    Standard InChI Key:  UDOBICLZEKUKCV-YXZULKJRSA-N

    Associated Targets(Human)

    Pyrimidinergic receptor P2Y6 717 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Pyrimidinergic receptor P2Y4 598 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Purinergic receptor P2Y2 1109 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    OCI-AML2 350 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    MCF7 126967 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    OVCAR-4 44535 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    COLO 205 50209 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    T47D 39041 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    PC-3 62116 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    SNB-19 46794 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Associated Targets(non-human)

    Orotidine phosphate decarboxylase 7 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Molecule Features

    Natural Product: NoOral: NoChemical Probe: NoParenteral: No
    Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
    Chirality: NoAvailability: NoProdrug: No

    Drug Indications

    MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Properties

    Molecular Weight: 340.18Molecular Weight (Monoisotopic): 340.0308AlogP: -3.03#Rotatable Bonds: 4
    Polar Surface Area: 191.54Molecular Species: ACIDHBA: 9HBD: 6
    #RO5 Violations: 1HBA (Lipinski): 12HBD (Lipinski): 6#RO5 Violations (Lipinski): 2
    CX Acidic pKa: 1.23CX Basic pKa: CX LogP: -2.40CX LogD: -6.86
    Aromatic Rings: 1Heavy Atoms: 22QED Weighted: 0.31Np Likeness Score: 1.03

    References

    1. El-Tayeb A, Qi A, Müller CE..  (2006)  Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.,  49  (24): [PMID:17125260] [10.1021/jm060848j]
    2. Bello AM, Konforte D, Poduch E, Furlonger C, Wei L, Liu Y, Lewis M, Pai EF, Paige CJ, Kotra LP..  (2009)  Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.,  52  (6): [PMID:19260677] [10.1021/jm801224t]
    3. Meza-Avina ME, Wei L, Liu Y, Poduch E, Bello AM, Mishra RK, Pai EF, Kotra LP..  (2010)  Structural determinants for the inhibitory ligands of orotidine-5'-monophosphate decarboxylase.,  18  (11): [PMID:20452222] [10.1016/j.bmc.2010.04.017]

    Source